BiondVax announced today that priming with universal flu vaccine before boosting with a conventional bird flu H5N1 vaccine (containing a single strain from Clade 1) resulted in mice exhibiting a significantly higher level of immunity to the strain contained in the conventional bird flu vaccine and in addition, broadened immunity to other H5N1 flu strains (from Clade 2).
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded two contracts to support the production and clinical testing of an investigational vaccine based on a strain of avian influenza, H5N1, which might have the potential to cause pandemic influenza.
According to the Food and Drug Administration (FDA) in the U.S., in clinical trials the nation's first bird flu vaccine is not as effective as was initially expected.
According to the top health official in the U.S., it will be three to five years before the United States can produce enough bird flu vaccine to inoculate its population against a potentially deadly outbreak in humans.
According to researchers an experimental vaccine produced to offer protection against the H5N1 strain of bird flu presently causing havoc across the world, only appears to work at the very highest doses.
The head of Indonesia's national committee on avian influenza has announced that scientists there have developed a bird flu vaccine for humans.
The Department of Health and Human Services in the United States has ordered more doses of the avian flu vaccine from the international pharmaceutical giant GlaxoSmithKline (GSK).
Doctors are beginning the first test in the United States of a vaccine designed to protect people against one form of bird flu should an outbreak of the virus occur in humans. While the vaccine under study is not designed to protect against the precise bird-flu virus causing the current outbreak in poultry and in people, scientists will learn whether it protects against another strain of the virus that infects birds and people.